Eloxx Q4 net loss $12.1M; CF Foundation awards up to $15.9M; new Alport program

Eloxx Pharmaceuticals, Inc.

2023-Q1 EPS reported -$5.36 vs consensus -$28.61 ▲ beat (+81.3%)

Net loss $12.1M in Q4 2021 ($0.14/sh); cash $42.3M; expects funding into Q2 2023.
CF Foundation therapeutic award up to $15.9M for ELX-02 CF program; $7.0M upfront.
Phase 2 CF expansion (ELX-02+ivacaftor) topline results expected by end of H1 2022.
New Alport syndrome program for ELX-02; proof-of-concept trial in up to 8 patients expected H2 2022.
ZKN-013 FAP mouse model: 50% reduction in polyp burden, 40% in polyp count; 50% survival benefit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.